Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Arizona
Clinical trial register · United States · industry-sponsored

Clinical Trials in Arizona, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9124 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 09 Oct 2026, 03:16 UTC
9124
Studies in scope
industry-sponsored, all four open statuses
4956
Recruiting now
open to new participants
2195
Lead sponsors
across recruiting studies
Top states
California 139 Florida 113 Illinois 72 New York 62 Texas 53
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca6 AbbVie3 Eli Lilly and Company2 Bristol-Myers Squibb2 Merck Sharp & Dohme LLC2
State
California139 Florida113 Illinois72 New York62 Texas53
All 48 states
Target enrolment
to

Trials with a site in Arizona

40 of 9124 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07154290Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
DrugsMarlotamig·Ubamatamab·Sarilumab
Regeneron Pharmaceuticals
Phase 2
300
Alabama, Arizona, California, Delaware, District of Columbia, Florida, Illinois, Indiana
2026-03-18
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Arizona, Arkansas, California, Florida, Illinois, Indiana, Louisiana, Maryland
2026-01-06
Recruiting
Hoffmann-La Roche
Phase 3
600
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-24
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri
2025-07-17
Recruiting
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT06810544Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor
DrugAbemaciclib
Tango Therapeutics, Inc.
Phase 1/2
191
Arizona, California, District of Columbia, Florida, Illinois, Massachusetts, Minnesota, New York
2025-03-24
Recruiting
Summit Therapeutics
Phase 3
780
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-02-27
Recruiting
AbbVie
Phase 2
150
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-01-20
Recruiting
AstraZeneca
Phase 3
1,160
Arizona, Arkansas, California, Connecticut, Delaware, Florida, Georgia, Idaho
2024-11-18
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Cetuximab·Irinotecan
Eli Lilly and Company
Phase 1
750
Alabama, Arizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan
2024-10-21
Active, closed
AstraZeneca
Phase 3
25
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky
2024-10-15
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Alabama, Arizona, California, Colorado, Florida, Idaho, Illinois, Kansas
2024-10-07
Active, closed
Hoffmann-La Roche
Phase 3
338
Arizona, California, Connecticut, Florida, Illinois, Maine, Massachusetts, Michigan
2024-09-23
Recruiting
AstraZeneca
Phase 3
675
Alaska, Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana
2024-04-11
Recruiting
A2 Biotherapeutics Inc.
Phase 1/2
474
Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Tennessee
2024-04-03
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2023-12-06
Active, closed
Summit Therapeutics
Phase 3
1,600
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-10-26
Active, closed
Regeneron Pharmaceuticals
Phase 2/3
160
Arizona, California, Colorado, Connecticut, Florida, Illinois, Louisiana, Mississippi
2023-08-08
Recruiting
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma
AstraZeneca
Phase 1
45
Arizona, California, Florida, Massachusetts, New Jersey, New York, North Carolina, Oregon
2023-07-12
Active, closed
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
NCT05812027Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers
TScan Therapeutics, Inc.
Observational
1,150
Arizona, California, Connecticut, Florida, Illinois, Kentucky, Michigan, Minnesota
2023-06-26
Active, closed
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
NCT05565417Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma
Immunitas Therapeutics
Phase 1/2
67
Arizona, Colorado, Florida, Oklahoma, Oregon, Tennessee, Texas, Virginia
2022-11-28
Recruiting
InSightec
Phase 3
30
Arizona, California, Florida, Maryland, North Carolina, Oregon, Rhode Island, Virginia
2022-08-12
Recruiting
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
NCT05245500Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor
DrugNavlimetostat
Bristol-Myers Squibb
Phase 1
336
Arizona, Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, New Jersey
2022-06-09
Active, closed
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
NCT05256290Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer
Black Diamond Therapeutics, Inc.
Phase 1/2
200
Alabama, Arizona, California, District of Columbia, Florida, Hawaii, Illinois, Kansas
2022-03-31
Active, closed
NGM Biopharmaceuticals, Inc
Phase 1
130
Arizona, California, Florida, Michigan, New York, Oklahoma, Texas
2022-03-31
Recruiting
AbbVie
Phase 3
768
Alabama, Arizona, California, Florida, Georgia, Hawaii, Illinois, Indiana
2022-03-25
Active, closed
AstraZeneca
Phase 3
791
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kentucky, Maryland
2022-02-18
Recruiting
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
NCT05098132Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
DrugsPembrolizumab KEYTRUDA·Pemetrexed·Carboplatin
Synthekine
Phase 1/2
364
Arizona, California, Connecticut, District of Columbia, Georgia, Illinois, Maryland, Massachusetts
2022-01-25
Active, closed
Gilead Sciences
Phase 3
603
Alaska, Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas
2021-11-17
Active, closed
A Study of NDI 1150-101 in Patients With Solid Tumors
NCT05128487Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer
DrugPembrolizumab
Nimbus Saturn, Inc.
Phase 1/2
106
Arizona, Connecticut, District of Columbia, Florida, Kentucky, Maryland, Michigan, Minnesota
2021-11-05
Recruiting
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
NCT04981119Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer
A2 Biotherapeutics Inc.
Observational
500
Arizona, California, Florida, Massachusetts, Minnesota, Missouri, New York, Ohio
2021-10-29
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
Guardant Health, Inc.
Observational
2,285
Alabama, Arizona, Arkansas, California, Colorado, Florida, Louisiana, Maine
2021-09-07
Active, closed
Daiichi Sankyo
Phase 3
605
Arizona, California, Florida, Illinois, Indiana, Kentucky, Louisiana, Maryland
2020-12-21
Active, closed
Candel Therapeutics, Inc.
Phase 2
90
Arizona, Connecticut, Illinois, Maryland, Minnesota, New York, Ohio, Pennsylvania
2020-10-13
Active, closed
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 2
184
Arizona, California, Florida, Georgia, Kentucky, Louisiana, Minnesota, New Mexico
2018-12-21
Active, closed
AstraZeneca
Phase 3
825
Arizona, California, Colorado, Florida, Illinois, Kansas, Kentucky, Maryland
2018-12-06
Active, closed
AbbVie
Phase 2
270
Alabama, Arizona, Arkansas, California, Colorado, Florida, Hawaii, Illinois
2018-10-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Indiana
2018-04-24
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Arizona, Maryland, Ohio, Texas
2018-01-26
Active, closed
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03170960Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
DrugsCabozantinib·Tecentriq·Atezolizumab
Exelixis
Phase 1
914
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2017-09-05
Active, closed
Eli Lilly and Company
Phase 1/2
857
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Louisiana
2017-05-02
Rows per page Showing 1–40 of 40
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-usa/state/arizona

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,124 studies in total at the last sync on 09 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 40 of those studies with a site in Arizona that also match the filters currently applied.

How many clinical trials are recruiting in Arizona?

19 of the 40 studies on this page are recruiting new participants as of the 09 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 21 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Arizona), 40 studies
PhaseStudiesRecruitingShare
Phase 318945%
Phase 1/27317.5%
Phase 15212.5%
Phase 25212.5%
Observational327.5%
Phase 2/3102.5%
Phase 4112.5%

Most active sponsors

Lead sponsors with the most studies (Arizona)
Lead sponsorStudiesRecruiting
AstraZeneca63
AbbVie32
A2 Biotherapeutics Inc.22
Bristol-Myers Squibb22
Eli Lilly and Company20
Hoffmann-La Roche21
Merck Sharp & Dohme LLC20
Regeneron Pharmaceuticals21
Summit Therapeutics21
Black Diamond Therapeutics, Inc.10
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.